Kwan, A.; Howard, F.; Winder, N.; Atkinson, E.; Jailani, A.; Patel, P.B.; Allen, R.; Ottewell, P.D.; Shaw, G.C.; Conner, J.;
et al. Macrophage Delivered HSV1716 Is Active against Triple Negative Breast Cancer. Future Pharmacol. 2022, 2, 444-459.
https://doi.org/10.3390/futurepharmacol2040029
AMA Style
Kwan A, Howard F, Winder N, Atkinson E, Jailani A, Patel PB, Allen R, Ottewell PD, Shaw GC, Conner J,
et al. Macrophage Delivered HSV1716 Is Active against Triple Negative Breast Cancer. Future Pharmacology. 2022; 2(4):444-459.
https://doi.org/10.3390/futurepharmacol2040029
Chicago/Turabian Style
Kwan, Amy, Faith Howard, Natalie Winder, Emer Atkinson, Ameera Jailani, Priya B. Patel, Richard Allen, Penelope D. Ottewell, Gary C. Shaw, Joe Conner,
and et al. 2022. "Macrophage Delivered HSV1716 Is Active against Triple Negative Breast Cancer" Future Pharmacology 2, no. 4: 444-459.
https://doi.org/10.3390/futurepharmacol2040029
APA Style
Kwan, A., Howard, F., Winder, N., Atkinson, E., Jailani, A., Patel, P. B., Allen, R., Ottewell, P. D., Shaw, G. C., Conner, J., Wilson, C., Srivastava, S. K., Danson, S. J., Lewis, C., Brown, J. E., & Muthana, M.
(2022). Macrophage Delivered HSV1716 Is Active against Triple Negative Breast Cancer. Future Pharmacology, 2(4), 444-459.
https://doi.org/10.3390/futurepharmacol2040029